Oncimmune Limited
Financials
Estimates*
| GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | 1.3m | 1.5m |
| % growth | (77 %) | (74 %) | 30 % | (63 %) | 682 % | 319 % | 16 % |
| EBITDA | (2.7m) | (3.3m) | (5.6m) | (6.9m) | (6.3m) | (2.7m) | (2.9m) |
| % EBITDA margin | (893 %) | (4070 %) | (5406 %) | (17646 %) | (2078 %) | (211 %) | (196 %) |
| Profit | (1.8m) | (4.0m) | (5.0m) | (5.5m) | (5.0m) | (2.9m) | (4.5m) |
| % profit margin | (596 %) | (5023 %) | (4788 %) | (14005 %) | (1643 %) | (224 %) | (305 %) |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Acquisition | |
| Total Funding | - | ||